Serum miR-22 is a novel prognostic marker for acute myeloid leukemia.

ABSTRACT:

Background

It has been demonstrated that aberrant expression of serum microRNAs is potential markers for the prognostic prediction of acute myeloid leukemia (AML). However, the clinical significance of serum miR-22 remained uncovered. In this study, we aimed to explore the potential prognostic value of serum miR-22 for AML.

Methods

Blood samples were collected from 124 patients with AML and 60 healthy individuals. Serum miR-22 level was detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and its potential clinical value was investigated.

Results

Our results showed that serum miR-22 expression was significantly downregulated in AML subjects compared to healthy controls. Serum miR-22 levels were lowest in AML patients with M4/M5 subtypes,

SUBMITTER: Qu H 

PROVIDER: S-EPMC7521259 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature